Introduction：Basic information about CAS 35121-78-9|Epoprostenol, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Epoprostenol |
|---|
| CAS Number | 35121-78-9 | Molecular Weight | 374.44700 |
|---|
| Density | 1.221g/cm3 | Boiling Point | 530.2ºC at 760mmHg |
|---|
| Molecular Formula | C20H31NaO5 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 182.1ºC |
|---|
Names
| Name | prostaglandin I2 |
|---|
| Synonym | More Synonyms |
|---|
Epoprostenol BiologicalActivity
| Description | Epoprostenol (Prostaglandin I2), the synthetic form of the natural prostaglandin derivative Prostacyclin (Prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH. Epoprostenol is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation[1]. |
|---|
| Related Catalog | Research Areas >>Cardiovascular Disease |
|---|
| Target | Human Endogenous Metabolite |
|---|
| References | [1]. Provencher S, et al.Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterialhypertension. PLoS One. 2015 Mar 20;10(3):e0120657. |
|---|
Chemical & Physical Properties
| Density | 1.221g/cm3 |
|---|
| Boiling Point | 530.2ºC at 760mmHg |
|---|
| Molecular Formula | C20H31NaO5 |
|---|
| Molecular Weight | 374.44700 |
|---|
| Flash Point | 182.1ºC |
|---|
| Exact Mass | 374.20700 |
|---|
| PSA | 89.82000 |
|---|
| LogP | 2.07380 |
|---|
| Index of Refraction | 1.611 |
|---|
| InChIKey | KAQKFAOMNZTLHT-OZUDYXHBSA-M |
|---|
| SMILES | CCCCCC(O)C=CC1C(O)CC2OC(=CCCCC(=O)[O-])CC21 |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- UK8008500
- CHEMICAL NAME :
- Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9-alpha,11-alpha,13E,15S)-
- CAS REGISTRY NUMBER :
- 35121-78-9
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C20-H32-O5
- MOLECULAR WEIGHT :
- 352.52
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 5 mg/kg
- SEX/DURATION :
- female 15-19 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- REFERENCE :
- GOBIDS Gynecologic and Obstetric Investigation. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.9- 1978- Volume(issue)/page/year: 33,193,1992
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 800 ng/kg
- SEX/DURATION :
- female 1-4 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Maternal Effects - other effects
- REFERENCE :
- JRPFA4 Journal of Reproduction and Fertility. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1960- Volume(issue)/page/year: 94,279,1992
|
Safety Information
| Hazard Codes | Xn |
|---|
| Risk Phrases | R20/21/22 |
|---|
| Safety Phrases | S22;S26;S36 |
|---|
Synonyms
| PGX |
| Epoprostenol |
| MFCD00135629 |
| Prostaglandin l2 |
| prostacyclin |
| Vasocyclin |
| PGl2 |
| ProstaglandinI |
| PGX(prostaglandin) |
| Cyclo-Prostin |
| EINECS 263-273-7 |
| Prostaglandin X |
